Difference between revisions of "Ovarian cancer laboratory findings"

Jump to: navigation, search
(One intermediate revision by the same user not shown)
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
 +
{{Ovarian cancer}}
  
{{Ovarian cancer}}
+
{{CMG}}; {{AE}} {{Hudakarman}}
 +
 
 +
 
 +
==Overview==
 +
 
 +
==Laboratory finding==
  
 
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How to Edit a Page|here]]  to learn about editing.
 
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How to Edit a Page|here]]  to learn about editing.

Revision as of 20:08, 12 July 2019

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer laboratory findings

CDC on Ovarian cancer laboratory findings

Ovarian cancer laboratory findings in the news

Blogs on Ovarian cancer laboratory findings

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.


Overview

Laboratory finding

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

  • Patients with ovarian cancer can present acutely or sub-acutely
  • If there is clinical suspicion of malignancy, the evaluation includes laboratory work, imaging and surgical exploration for the definite diagnosis
  • Routine lab work
    • CBC
    • CBP
  • Serum biomarkers of epithelial ovarian cancer (EOC):
    • CA 125
      • Considered the best for ovarian cancer detection, therapeutic monitoring, and detection of the tumor recurrence
      • Postmenopausal woman: should be measured
      • Premenopausal woman: should be measured only if US shows highly suspicious malignant mass
    • HE4
      • CA125 and HE4 are used together to increase the sensitivity and specificity of ovarian cancer detection
      • Risk of Ovarian Malignancy Algorithm (ROMA) is used to decide if the patient has a high risk or low-risk malignant disease based on:
        • CA125 and HE4 levels
        • Menopausal status of the woman
    • OVA1
  • Serum biomarkers of the germ cell and sex cord-stromal ovarian cancer:
    • AFP: alpha-fetoprotein
    • hCG: human chorionic gonadotropin
    • LDH: lactate dehydrogenase
    • E2: estradiol
    • Inhibin
    • Testost: testosterone
    • Andro: androstenedione
    • DHEA: dehydroepiandrostenedione
    • AMH: anti-Müllerian hormone


References


Linked-in.jpg